| Bid | 13.73 |
| Market Cap | 1.26B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.13 |
| PE Ratio (ttm) | -4.4 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 14.95 |
| Volume | 418,215 |
| Avg. Volume (20D) | 742,937 |
| Open | 14.02 |
| Previous Close | 13.93 |
| Day's Range | 13.65 - 14.13 |
| 52-Week Range | 13.51 - 20.31 |
| Beta | undefined |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...
Analyst Forecast
According to 10 analyst ratings, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 117.63% from the latest price.
Next Earnings Release
Analysts project revenue of $31.31M, reflecting a 1.00% YoY growth and earnings per share of -1.2, making a 11.11% increase YoY.
1 month ago · businesswire.com
Arcus Biosciences to Participate in Two Upcoming Investor ConferencesHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
